The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis
The clinical role of deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) in gastric cancer (GC) is still controversial. We aimed to analyze the relationship between dMMR/MSI-H and clinicopathological features along with survival. Patients who were diagnosed with GC at the th...
Saved in:
| Published in | Frontiers in oncology Vol. 11; p. 712760 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
25.11.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2234-943X 2234-943X |
| DOI | 10.3389/fonc.2021.712760 |
Cover
| Abstract | The clinical role of deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) in gastric cancer (GC) is still controversial. We aimed to analyze the relationship between dMMR/MSI-H and clinicopathological features along with survival.
Patients who were diagnosed with GC at the three big cancer centers in China from 2015 to 2020 were evaluated retrospectively. MMR/MSI status was assessed using immunohistochemistry/PCR. Clinical and pathological data were collected from the medical record system.
A total of 196 patients with dMMR/MSI-H status were enrolled for analysis. The prevalence of MSI-H/dMMR in GC was 6.6%. Another 694 proficient MMR (pMMR) GC patients were enrolled for comparison. Compared with pMMR patients, dMMR/MSI-H patients were associated with older age, female predominance, distal location in the stomach, earlier TNM stage, intestinal subtype, better differentiation, and more negative HER2 status. The median overall survival (OS) of the dMMR/MSI-H group was better than that of the pMMR/microsatellite stability (MSS) group (not reached
. 53.9 months,
= 0.014). Adjuvant chemotherapy had no impact in both disease-free survival (DFS) and OS of dMMR/MSI-H patients (
= 0.135 and 0.818, respectively). dMMR/MSI-H patients had poorer response and progression-free survival (PFS) of first-line chemotherapy, though they were statistically significant (
= 0.361 and 0.124, respectively).
dMMR/MSI-H GC patients have specific clinicopathological characteristics and better prognosis than pMMR patients. |
|---|---|
| AbstractList | The clinical role of deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) in gastric cancer (GC) is still controversial. We aimed to analyze the relationship between dMMR/MSI-H and clinicopathological features along with survival.
Patients who were diagnosed with GC at the three big cancer centers in China from 2015 to 2020 were evaluated retrospectively. MMR/MSI status was assessed using immunohistochemistry/PCR. Clinical and pathological data were collected from the medical record system.
A total of 196 patients with dMMR/MSI-H status were enrolled for analysis. The prevalence of MSI-H/dMMR in GC was 6.6%. Another 694 proficient MMR (pMMR) GC patients were enrolled for comparison. Compared with pMMR patients, dMMR/MSI-H patients were associated with older age, female predominance, distal location in the stomach, earlier TNM stage, intestinal subtype, better differentiation, and more negative HER2 status. The median overall survival (OS) of the dMMR/MSI-H group was better than that of the pMMR/microsatellite stability (MSS) group (not reached
. 53.9 months,
= 0.014). Adjuvant chemotherapy had no impact in both disease-free survival (DFS) and OS of dMMR/MSI-H patients (
= 0.135 and 0.818, respectively). dMMR/MSI-H patients had poorer response and progression-free survival (PFS) of first-line chemotherapy, though they were statistically significant (
= 0.361 and 0.124, respectively).
dMMR/MSI-H GC patients have specific clinicopathological characteristics and better prognosis than pMMR patients. The clinical role of deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) in gastric cancer (GC) is still controversial. We aimed to analyze the relationship between dMMR/MSI-H and clinicopathological features along with survival.BACKGROUNDThe clinical role of deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) in gastric cancer (GC) is still controversial. We aimed to analyze the relationship between dMMR/MSI-H and clinicopathological features along with survival.Patients who were diagnosed with GC at the three big cancer centers in China from 2015 to 2020 were evaluated retrospectively. MMR/MSI status was assessed using immunohistochemistry/PCR. Clinical and pathological data were collected from the medical record system.METHODSPatients who were diagnosed with GC at the three big cancer centers in China from 2015 to 2020 were evaluated retrospectively. MMR/MSI status was assessed using immunohistochemistry/PCR. Clinical and pathological data were collected from the medical record system.A total of 196 patients with dMMR/MSI-H status were enrolled for analysis. The prevalence of MSI-H/dMMR in GC was 6.6%. Another 694 proficient MMR (pMMR) GC patients were enrolled for comparison. Compared with pMMR patients, dMMR/MSI-H patients were associated with older age, female predominance, distal location in the stomach, earlier TNM stage, intestinal subtype, better differentiation, and more negative HER2 status. The median overall survival (OS) of the dMMR/MSI-H group was better than that of the pMMR/microsatellite stability (MSS) group (not reached vs. 53.9 months, p = 0.014). Adjuvant chemotherapy had no impact in both disease-free survival (DFS) and OS of dMMR/MSI-H patients (p = 0.135 and 0.818, respectively). dMMR/MSI-H patients had poorer response and progression-free survival (PFS) of first-line chemotherapy, though they were statistically significant (p = 0.361 and 0.124, respectively).RESULTSA total of 196 patients with dMMR/MSI-H status were enrolled for analysis. The prevalence of MSI-H/dMMR in GC was 6.6%. Another 694 proficient MMR (pMMR) GC patients were enrolled for comparison. Compared with pMMR patients, dMMR/MSI-H patients were associated with older age, female predominance, distal location in the stomach, earlier TNM stage, intestinal subtype, better differentiation, and more negative HER2 status. The median overall survival (OS) of the dMMR/MSI-H group was better than that of the pMMR/microsatellite stability (MSS) group (not reached vs. 53.9 months, p = 0.014). Adjuvant chemotherapy had no impact in both disease-free survival (DFS) and OS of dMMR/MSI-H patients (p = 0.135 and 0.818, respectively). dMMR/MSI-H patients had poorer response and progression-free survival (PFS) of first-line chemotherapy, though they were statistically significant (p = 0.361 and 0.124, respectively).dMMR/MSI-H GC patients have specific clinicopathological characteristics and better prognosis than pMMR patients.CONCLUSIONSdMMR/MSI-H GC patients have specific clinicopathological characteristics and better prognosis than pMMR patients. BackgroundThe clinical role of deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) in gastric cancer (GC) is still controversial. We aimed to analyze the relationship between dMMR/MSI-H and clinicopathological features along with survival.MethodsPatients who were diagnosed with GC at the three big cancer centers in China from 2015 to 2020 were evaluated retrospectively. MMR/MSI status was assessed using immunohistochemistry/PCR. Clinical and pathological data were collected from the medical record system.ResultsA total of 196 patients with dMMR/MSI-H status were enrolled for analysis. The prevalence of MSI-H/dMMR in GC was 6.6%. Another 694 proficient MMR (pMMR) GC patients were enrolled for comparison. Compared with pMMR patients, dMMR/MSI-H patients were associated with older age, female predominance, distal location in the stomach, earlier TNM stage, intestinal subtype, better differentiation, and more negative HER2 status. The median overall survival (OS) of the dMMR/MSI-H group was better than that of the pMMR/microsatellite stability (MSS) group (not reached vs. 53.9 months, p = 0.014). Adjuvant chemotherapy had no impact in both disease-free survival (DFS) and OS of dMMR/MSI-H patients (p = 0.135 and 0.818, respectively). dMMR/MSI-H patients had poorer response and progression-free survival (PFS) of first-line chemotherapy, though they were statistically significant (p = 0.361 and 0.124, respectively).ConclusionsdMMR/MSI-H GC patients have specific clinicopathological characteristics and better prognosis than pMMR patients. |
| Author | Ma, Yue Cui, Yue-Hong Zhou, Zhi-Wei Xu, Rui-Hua Xu, Jian-Ying Yang, Li-Qiong Guan, Wen-Long Li, Jia-Yu Zhang, Yan-Qiao Liu, Tian-Shu Sun, Yu-Ting Qiu, Miao-Zhen Wang, Feng-Hua |
| AuthorAffiliation | 4 Department of Gastric Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine , Guangzhou , China 1 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine , Guangzhou , China 2 Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital , Harbin , China 3 Department of Medical Oncology, Zhongshan Hospital, Fudan University , Shanghai , China |
| AuthorAffiliation_xml | – name: 2 Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital , Harbin , China – name: 4 Department of Gastric Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine , Guangzhou , China – name: 1 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine , Guangzhou , China – name: 3 Department of Medical Oncology, Zhongshan Hospital, Fudan University , Shanghai , China |
| Author_xml | – sequence: 1 givenname: Wen-Long surname: Guan fullname: Guan, Wen-Long – sequence: 2 givenname: Yue surname: Ma fullname: Ma, Yue – sequence: 3 givenname: Yue-Hong surname: Cui fullname: Cui, Yue-Hong – sequence: 4 givenname: Tian-Shu surname: Liu fullname: Liu, Tian-Shu – sequence: 5 givenname: Yan-Qiao surname: Zhang fullname: Zhang, Yan-Qiao – sequence: 6 givenname: Zhi-Wei surname: Zhou fullname: Zhou, Zhi-Wei – sequence: 7 givenname: Jian-Ying surname: Xu fullname: Xu, Jian-Ying – sequence: 8 givenname: Li-Qiong surname: Yang fullname: Yang, Li-Qiong – sequence: 9 givenname: Jia-Yu surname: Li fullname: Li, Jia-Yu – sequence: 10 givenname: Yu-Ting surname: Sun fullname: Sun, Yu-Ting – sequence: 11 givenname: Rui-Hua surname: Xu fullname: Xu, Rui-Hua – sequence: 12 givenname: Feng-Hua surname: Wang fullname: Wang, Feng-Hua – sequence: 13 givenname: Miao-Zhen surname: Qiu fullname: Qiu, Miao-Zhen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34900669$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1Uk1vFCEYJqbG1tq7J8PRy658DQweTDYbrZu0sdEavREGmF2aGdgCY9J_L-O2pjWRC7zwfPDmfV6CoxCDA-A1RktKW_muj8EsCSJ4KTARHD0DJ4RQtpCM_jx6dD4GZznfoLp4gzCiL8AxZbJWXJ4Af71zcDPutSkw9vDS51EXs4Nf3V77BL8VXaYMY4BXKW5DzD7PsCtdvAslwx--7OC5ziV5A9c6GJfewxW8nIbiTUW4BFdBD3eV9wo87_WQ3dn9fgq-f_p4vf68uPhyvlmvLhaGcVIWtSHrSGckla0QiHFqjbBCW4Y73QhmEKeIC95w7DByrRadINawBsue9K2lp2Bz0LVR36h98qNOdypqr_5cxLRVOtXfDU5JJnDTdqZlLWbUYIkb62wjpDOiR4hVrQ8Hrf3Ujc7OHSU9PBF9-hL8Tm3jL9XypiFUVoG39wIp3k4uFzX6bNww6ODilBXhGCFR_UmFvnns9dfkYVYVwA8Ak2LOyfXK-DoeH2drPyiM1JwLNedCzblQh1xUIvqH-KD9X8pvyoi6sg |
| CitedBy_id | crossref_primary_10_1177_17588359241231259 crossref_primary_10_1186_s13045_023_01451_3 crossref_primary_10_1007_s10120_024_01523_4 crossref_primary_10_3389_fimmu_2024_1391038 crossref_primary_10_3389_fimmu_2024_1471399 crossref_primary_10_3390_cancers15164114 crossref_primary_10_1007_s10120_024_01483_9 crossref_primary_10_3390_cancers17030412 crossref_primary_10_3390_cancers15010074 crossref_primary_10_1007_s00432_022_04408_0 crossref_primary_10_17116_onkolog20231204178 crossref_primary_10_1038_s41598_024_80450_x crossref_primary_10_1093_oncolo_oyad108 crossref_primary_10_1186_s12935_024_03521_z crossref_primary_10_1038_s41598_024_81764_6 crossref_primary_10_1016_j_esmoop_2024_102971 crossref_primary_10_1089_adt_2023_141 crossref_primary_10_1200_PO_22_00463 crossref_primary_10_7759_cureus_49412 crossref_primary_10_1007_s12029_023_01003_5 crossref_primary_10_3390_ijms23158726 crossref_primary_10_1111_his_14830 crossref_primary_10_1186_s13027_023_00489_9 crossref_primary_10_1245_s10434_024_16030_0 |
| Cites_doi | 10.1002/ijc.26399 10.1111/j.1440-1746.2010.06487.x 10.1038/sj.bjc.6604756 10.1016/S0140-6736(18)31257-1 10.1016/j.surg.2005.08.021 10.1038/nature13480 10.1001/jamaoncol.2016.6762 10.1002/cam4.1372 10.1001/archsurg.2009.42 10.1016/j.humpath.2013.09.004 10.3389/fonc.2020.01269 10.1245/s10434-015-4931-3 10.1200/JCO.2021.39.3_suppl.244 10.1245/s10434-009-0580-8 10.1200/JCO.2009.27.1825 10.1002/jso.21220 10.1634/theoncologist.2019-0419 10.1001/jamaoncol.2018.0013 10.1007/s10120-016-0594-4 10.1200/jco.2015.33.15_suppl.lba100 10.4143/crt.2020.173 10.1002/ijc.29449 10.1200/JCO.19.01124 10.1056/NEJMoa022289 10.1016/j.ejca.2018.02.014 10.1038/sj.bjc.6604738 10.1002/jso.23618 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 Guan, Ma, Cui, Liu, Zhang, Zhou, Xu, Yang, Li, Sun, Xu, Wang and Qiu. Copyright © 2021 Guan, Ma, Cui, Liu, Zhang, Zhou, Xu, Yang, Li, Sun, Xu, Wang and Qiu 2021 Guan, Ma, Cui, Liu, Zhang, Zhou, Xu, Yang, Li, Sun, Xu, Wang and Qiu |
| Copyright_xml | – notice: Copyright © 2021 Guan, Ma, Cui, Liu, Zhang, Zhou, Xu, Yang, Li, Sun, Xu, Wang and Qiu. – notice: Copyright © 2021 Guan, Ma, Cui, Liu, Zhang, Zhou, Xu, Yang, Li, Sun, Xu, Wang and Qiu 2021 Guan, Ma, Cui, Liu, Zhang, Zhou, Xu, Yang, Li, Sun, Xu, Wang and Qiu |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fonc.2021.712760 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2234-943X |
| ExternalDocumentID | oai_doaj_org_article_947158bc848143c1915ded579ec7f004 PMC8655239 34900669 10_3389_fonc_2021_712760 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-202de2bc9398770463dc7d7ad41ba574c0630676561e10e8a7b72dc4519f2f8d3 |
| IEDL.DBID | M48 |
| ISSN | 2234-943X |
| IngestDate | Wed Aug 27 01:24:49 EDT 2025 Thu Aug 21 14:35:25 EDT 2025 Fri Sep 05 14:32:50 EDT 2025 Thu Apr 03 07:07:39 EDT 2025 Thu Apr 24 22:59:52 EDT 2025 Tue Jul 01 02:46:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | adjuvant chemotherapy MSI MMR gastric cancer prognosis |
| Language | English |
| License | Copyright © 2021 Guan, Ma, Cui, Liu, Zhang, Zhou, Xu, Yang, Li, Sun, Xu, Wang and Qiu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-202de2bc9398770463dc7d7ad41ba574c0630676561e10e8a7b72dc4519f2f8d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Alberto Biondi, Catholic University of the Sacred Heart, Italy These authors have contributed equally to this work Reviewed by: Chenyu Lin, The Ohio State University, United States; Jia Wei, Nanjing Drum Tower Hospital, China This article was submitted to Gastrointestinal Cancers, a section of the journal Frontiers in Oncology |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2021.712760 |
| PMID | 34900669 |
| PQID | 2610078482 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_947158bc848143c1915ded579ec7f004 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8655239 proquest_miscellaneous_2610078482 pubmed_primary_34900669 crossref_citationtrail_10_3389_fonc_2021_712760 crossref_primary_10_3389_fonc_2021_712760 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-11-25 |
| PublicationDateYYYYMMDD | 2021-11-25 |
| PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in oncology |
| PublicationTitleAlternate | Front Oncol |
| PublicationYear | 2021 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Kim (B6) 2015; 137 Choi (B20) 2014; 110 Ribic (B16) 2003; 349 Boland (B11) 1998; 58 An (B5) 2020; 52 Michel (B21) 2008; 99 Beghelli (B10) 2006; 139 Sargent (B17) 2010; 28 Hewitt (B3) 2018; 94 Seo (B18) 2009; 99 Marrelli (B13) 2016; 23 An (B4) 2012; 131 Le (B15) 2015; 372 Vanderwalde (B27) 2018; 7 Tsai (B24) 2020; 25 Oki (B9) 2009; 16 Vos (B25) 2021 Lee (B23) 2008; 99 Bass (B1) 2014; 513 Kim (B22) 2014; 45 Corso (B12) 2009; 144 Pietrantonio (B14) 2019; 37 Zhang (B8) 2018; 11 Kim (B7) 2011; 26 Shitara (B29) 2018; 392 Smyth (B2) 2017; 3 Giampieri (B26) 2016; 20 Fuchs (B28) 2018; 4 Cai (B19) 2020; 10 |
| References_xml | – volume: 131 year: 2012 ident: B4 article-title: Microsatellite Instability in Sporadic Gastric Cancer: Its Prognostic Role and Guidance for 5-FU Based Chemotherapy After R0 Resection publication-title: Int J Cancer doi: 10.1002/ijc.26399 – volume: 26 year: 2011 ident: B7 article-title: High Microsatellite Instability Predicts Good Prognosis in Intestinal-Type Gastric Cancers publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2010.06487.x – volume: 99 year: 2008 ident: B21 article-title: High Density of FOXP3-Positive T Cells Infiltrating Colorectal Cancers With Microsatellite Instability publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604756 – volume: 392 year: 2018 ident: B29 article-title: Pembrolizumab Versus Paclitaxel for Previously Treated, Advanced Gastric or Gastro-Oesophageal Junction Cancer (KEYNOTE-061): A Randomised, Open-Label, Controlled, Phase 3 Trial publication-title: Lancet doi: 10.1016/S0140-6736(18)31257-1 – volume: 139 year: 2006 ident: B10 article-title: Microsatellite Instability in Gastric Cancer Is Associated With Better Prognosis in Only Stage II Cancers publication-title: Surgery doi: 10.1016/j.surg.2005.08.021 – volume: 513 year: 2014 ident: B1 article-title: Comprehensive Molecular Characterization of Gastric Adenocarcinoma publication-title: Nature doi: 10.1038/nature13480 – volume: 3 year: 2017 ident: B2 article-title: Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.6762 – volume: 7 year: 2018 ident: B27 article-title: Microsatellite Instability Status Determined by Next-Generation Sequencing and Compared With PD-L1 and Tumor Mutational Burden in 11,348 Patients publication-title: Cancer Med doi: 10.1002/cam4.1372 – volume: 144 year: 2009 ident: B12 article-title: Correlation of Microsatellite Instability at Multiple Loci With Long-Term Survival in Advanced Gastric Carcinoma publication-title: Arch Surg doi: 10.1001/archsurg.2009.42 – volume: 45 year: 2014 ident: B22 article-title: Prognostic Implications of Tumor-Infiltrating FoxP3+ Regulatory T Cells and CD8+ Cytotoxic T Cells in Microsatellite-Unstable Gastric Cancers publication-title: Hum Pathol doi: 10.1016/j.humpath.2013.09.004 – volume: 10 year: 2020 ident: B19 article-title: The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer publication-title: Front Oncol doi: 10.3389/fonc.2020.01269 – volume: 23 year: 2016 ident: B13 article-title: Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-Cardia Gastric Cancer publication-title: Ann Surg Oncol doi: 10.1245/s10434-015-4931-3 – start-page: abstr 244 year: 2021 ident: B25 article-title: The Interaction Between Microsatellite Instability High (MSI-High) Gastric Cancer and Chemotherapy on Survival publication-title: J Clin Oncol doi: 10.1200/JCO.2021.39.3_suppl.244 – volume: 16 year: 2009 ident: B9 article-title: Chemosensitivity and Survival in Gastric Cancer Patients With Microsatellite Instability publication-title: Ann Surg Oncol doi: 10.1245/s10434-009-0580-8 – volume: 58 year: 1998 ident: B11 article-title: A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instability in Colorectal Cancer publication-title: Cancer Res – volume: 28 year: 2010 ident: B17 article-title: Defective Mismatch Repair as a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.1825 – volume: 99 year: 2009 ident: B18 article-title: Clinicopathologic Characteristics and Outcomes of Gastric Cancers With the MSI-H Phenotype publication-title: J Surg Oncol doi: 10.1002/jso.21220 – volume: 25 year: 2020 ident: B24 article-title: Is Adjuvant Chemotherapy Necessary for Patients With Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched publication-title: Oncologist doi: 10.1634/theoncologist.2019-0419 – volume: 4 start-page: e180013 year: 2018 ident: B28 article-title: Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.0013 – volume: 20 year: 2016 ident: B26 article-title: Mismatch Repair Deficiency may Affect Clinical Outcome Through Immune Response Activation in Metastatic Gastric Cancer Patients Receiving First-Line Chemotherapy publication-title: Gastric Cancer doi: 10.1007/s10120-016-0594-4 – volume: 372 year: 2015 ident: B15 article-title: PD-1 Blockade in Tumors With Mismatch-Repair Deficiency publication-title: N Engl J Med doi: 10.1200/jco.2015.33.15_suppl.lba100 – volume: 52 year: 2020 ident: B5 article-title: A Multi-Cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status After Recurrence of Resectable Gastric Cancer publication-title: Cancer Res Treat doi: 10.4143/crt.2020.173 – volume: 137 year: 2015 ident: B6 article-title: The Benefit of Microsatellite Instability Is Attenuated by Chemotherapy in Stage II and Stage III Gastric Cancer: Results From a Large Cohort With Subgroup Analyses publication-title: Int J Cancer doi: 10.1002/ijc.29449 – volume: 37 year: 2019 ident: B14 article-title: Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer publication-title: J Clin Oncol doi: 10.1200/JCO.19.01124 – volume: 349 year: 2003 ident: B16 article-title: Tumor Microsatellite-Instability Status as a Predictor of Benefit From Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa022289 – volume: 94 year: 2018 ident: B3 article-title: Epstein-Barr Virus and Mismatch Repair Deficiency Status Differ Between Oesophageal and Gastric Cancer: A Large Multi-Centre Study publication-title: Eur J Cancer doi: 10.1016/j.ejca.2018.02.014 – volume: 11 year: 2018 ident: B8 article-title: Clinicopathological Features and Prognostic Value of Mismatch Repair Protein Deficiency in Gastric Cancer publication-title: Int J Clin Exp Pathol – volume: 99 year: 2008 ident: B23 article-title: Prognostic Implications of Type and Density of Tumour-Infiltrating Lymphocytes in Gastric Cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604738 – volume: 110 year: 2014 ident: B20 article-title: Is Microsatellite Instability a Prognostic Marker in Gastric Cancer? A Systematic Review with Meta-Analysis publication-title: J Surg Oncol doi: 10.1002/jso.23618 |
| SSID | ssj0000650103 |
| Score | 2.429825 |
| Snippet | The clinical role of deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) in gastric cancer (GC) is still controversial. We aimed to... BackgroundThe clinical role of deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) in gastric cancer (GC) is still controversial. We... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 712760 |
| SubjectTerms | adjuvant chemotherapy gastric cancer MMR MSI Oncology prognosis |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gL4qNAClRG6oVD2Nixd2xupWoplRb1QEVvlmM72khVUiW7_x9PnN3uIgQXromjjOaN7Tey5w0hJ0rZwoaYploZilwEyXOrmMx1KKyy3rLCY73z4vv88kZc3crbnVZfeCcsyQMnx810XD2lqhzKvovSxfRC-uAl6OCgnpRAC13sJFNpDZbYwCCdS8YsTM_qrkXFQs4-AeMwKlI-7EOjXP-fOObvVyV39p6LZ-TpRBrpaTL2OXkU2hfk8WI6Fn9Jmgg2_TbWO9KupotmiDzULWlk17bpKRLK9UC7ll73HV6sawYcdp0kVQf6s1kt6VeLHTwcPcMw6D_TUzrW5qJFoacb7ZJDcnNx_uPsMp96KOROzPkqTgLuA6-cLrUCQHkw78CD9YJVVoJwqLk1h8jqWGBFUBYq4N6h6EzNa-XLV-Sg7drwhlAoSwms1mVkUMJFn8q5F95V4Bj3NdQZmW08atwkMI59Lu5MTDQQA4MYGMTAJAwy8nH7xX0S1_jL2C8I0nYcymKPD2KwmClYzL-CJSMfNhCbOI3wbMS2oVsPJiaSyJaE4hl5nSDf_qoUGpmZzgjsBcOeLftv2mY5SnVj2S8v9dH_MP4teYL-wEJILt-Rg1W_Du8jI1pVx2Pw_wJ96QeC priority: 102 providerName: Directory of Open Access Journals |
| Title | The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34900669 https://www.proquest.com/docview/2610078482 https://pubmed.ncbi.nlm.nih.gov/PMC8655239 https://doaj.org/article/947158bc848143c1915ded579ec7f004 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA9ygvgifls_jgi--NC75qtpBJHz8O4UVu7BxX0LaZLeFo5W213Q_96Ztru6sgi-FNqmbZqZdH7TyfyGkFdF4TIXwU11KmapjIqnrmAqNTFzhQuOZQHznWef84u5_LRQi9_p0dMA9ntdO6wnNe-uj358__kOJvxb9DjB3h5XbYNkhJwdacZ1Dg78zSFahAv5JrA_fpcVFjXAanNcyNRIsRjjlntvsmOnBjr_fRj076WUf9ims7vkzgQq6cmoBffIjdjcJ7dmU9j8AalBGejHIR-SthWd1T3gVL-kgL5d3VEEnOuetg297FpceFf32OxypFzt6dd6taTnDit8eHqKatK9oSd0yN3FHsWObrhNHpL52YcvpxfpVGMh9TLnK5gkPEReeiNMoTXShwWvg3ZBstIpLT1ycuUaUB-LLIuF06XmwSMpTcWrIohH5KBpm_iEUC2E0qwyAhCW9DCmKg8y-FJ7xkOlq4Qcb0bU-omAHOtgXFtwRFAGFmVgUQZ2lEFCXm-v-DaSb_yj7XsU0rYd0mYPB9ruyk6z0BowxaooPdYQkMKDr6pCDEqb6HUFn4uEvNyI2MI0w9iJa2K77i04moimZMET8ngU-fZRQhpEbiYhekcZdvqye6aplwOVN6YFc2Ge_seLPiO3cQ_zIbl6Tg5W3Tq-AGC0Kg-HHwqwPV-ww0H3fwHSUQsG |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Impact+of+Mismatch+Repair+Status+on+Prognosis+of+Patients+With+Gastric+Cancer%3A+A+Multicenter+Analysis&rft.jtitle=Frontiers+in+oncology&rft.au=Guan%2C+Wen-Long&rft.au=Ma%2C+Yue&rft.au=Cui%2C+Yue-Hong&rft.au=Liu%2C+Tian-Shu&rft.date=2021-11-25&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=11&rft_id=info:doi/10.3389%2Ffonc.2021.712760&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fonc_2021_712760 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |